FRESCO-2: Fruquintinib improves OS in heavily pretreated mCRC
Fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR*-1, -2, and -3, significantly improves overall survival (OS) in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to the FRESCO-2** trial presented at ESMO 2022.

New Molecule

3 New

New Dosage Strength

1 New

Markings
Shape
Form
Color 1
Color 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in